Mphasis Q4 FY26: ₹3,200 target after 14% profit rise

Nuvama has reiterated its Buy rating on Mphasis, setting a target price of ₹3,200, implying a potential 42% upside from recent trading levels. The call follows Mphasis’s Q4 FY26 results, where the company delivered strong year-on-year growth in both revenue and profit.

The quarter also reinforced a key part of the investment debate around mid-cap IT: whether AI-led deal momentum can translate into steady revenue conversion, even as the broader industry faces pricing pressure and shifting client budgets. Alongside Nuvama, other brokerages have also updated their stance, with Morgan Stanley upgrading and raising its target, while parts of the market remain cautious on valuation and visibility.

Nuvama’s thesis: results beat and AI-heavy pipeline

Nuvama’s positive view is anchored in the company’s Q4 FY26 performance and its positioning in AI-led programs. A key data point highlighted is that 64% of new deal wins in Q4 FY26 were AI-related, supporting the argument that Mphasis is participating meaningfully in the current wave of enterprise AI adoption.

The company reported total contract value (TCV) of $107 million for the quarter, with Nuvama pointing to Mphasis’s ability to convert a strong deal pipeline into measurable financial results. The brokerage also framed the Q4 FY26 growth as notable because it exceeded the company’s longer-term growth benchmark.

Q4 FY26 financial performance: revenue and profit rise

Mphasis reported revenue growth of 14.36% year-on-year to ₹4,242.67 crore in Q4 FY26. Net profit increased 14.14% year-on-year to ₹509.64 crore.

These results were described as surpassing the company’s five-year sales CAGR of 9.97%, supporting the view that execution improved meaningfully in the quarter. The numbers strengthened the narrative that deal wins are increasingly flowing into reported revenue.

AI deal mix and what it signals for execution

Mphasis’s AI focus stood out in the deal commentary. With 64% of Q4 FY26 new deal wins tied to AI, investors are watching whether this mix sustains and whether the company can maintain conversion from AI-linked wins into multi-quarter revenue streams.

At the same time, the broader industry context matters. The article flags that AI can be both a growth driver and a pricing disruptor, depending on how spending shifts between new AI work and traditional IT services.

BFSI remains the growth engine, but concentration risk persists

Mphasis’s Banking, Financial Services, and Insurance (BFSI) segment posted 17.4% year-on-year growth in Q4 FY26, reinforcing BFSI as a key growth driver.

But the same concentration is also framed as a risk. Heavy reliance on a single vertical can expose the company to sector-specific slowdowns, particularly if banking and insurance clients cut discretionary technology spending.

Valuation: premium multiples in a cautious IT tape

Despite the quarter’s performance, the stock’s valuation remains a central issue. Mphasis is cited as trading at a P/E of about 23-24x, above the IT sector average of about 21x. The multiple is still below specialists such as Persistent Systems and Coforge (noted as over 39x), but well above larger peers such as Wipro (15.95x).

The valuation premium is being debated in an environment where the Indian IT industry faces potential AI-led price compression in traditional services.

Industry risk backdrop: AI-driven deflation and budget reallocation

Kotak Institutional Equities estimates AI-driven deflationary pressures could reduce traditional IT services revenues by a base-case 3.5% annually, with potential implications for margins and future growth.

The article also points to the risk that AI spending could shift client budgets away from traditional work, creating pricing pressure on renewals and new projects. That dynamic is especially relevant for mid-cap IT firms that depend on continued deal flow and steady realization.

Margins under watch: FY26 operating margin around 15.3%

The sustainability of profitability is another key monitorable. Mphasis’s operating margins are cited at around 15.3% for FY26, and investors are watching whether this can hold amid continued investment in AI capabilities and broader pricing pressure.

The stock’s performance over the past year, down 7-9%, is presented as reflecting these concerns, particularly around premium valuation, margin durability, and growth visibility.

What brokerages are saying: targets, upgrades, and rerating triggers

Beyond Nuvama’s ₹3,200 target, the coverage set includes Morgan Stanley’s more constructive view. Morgan Stanley upgraded Mphasis from Equalweight to Overweight, and Investing.com reported a new price target of INR 3,500 from INR 2,650, citing improvements in growth outlook.

The Morgan Stanley note pointed to several factors: an uptick in the qualified deal pipeline, the drag from the Logistics and Transportation vertical appearing to ease, and improving conversion of deal win TCV into revenue. It also raised earnings per share estimates by 5.7% for FY27 and 5.2% for FY28, and stated that the new target is based on a 30x P/E multiple applied to June 2027 estimates, alongside higher long-term growth and margin assumptions.

Separate commentary in the provided text also references Morgan Stanley raising a target to 3,625 and raising revenue growth forecasts by 50 basis points for FY27 and 100 basis points for FY28.

At the same time, the broader analyst set is described as leaning to Outperform, with average price targets generally in the ₹2,700-₹2,800 range, though the dispersion is wide.

Key numbers at a glance

Brokerage targets and ratings mentioned

Outlook and what investors are likely to track next

The company anticipates high single to low double-digit growth for FY27, even as the sector faces economic uncertainty and competition. For investors, the next set of questions is less about one quarter’s beat and more about repeatability: sustained deal wins, conversion discipline, and whether margins can hold while investing in AI.

The near-term focus remains on AI-led execution, BFSI demand stability, and whether premium valuation can be supported by consistent quarterly delivery. Broker commentary suggests the next rerating debate will hinge on pipeline quality and revenue cadence, rather than deal headlines alone.